A study to correlate histopathology, biochemical marker and immunohistochemical expression of sex-sterol receptors in prostatic growth

Sukla Naskar, Soumya Kanti Kundu, Nirmal Kumar Bhattacharyya, Pranab Kumar Bhattacharyya, Anup Kumar Kundu
Departments Pathology, Calcutta National Medical College, 2Medical College, 3School of Tropical Medicine, 4Consultant in Nuclear Medicine, R.N. Tagore Institute of Cardiac Sciences. 5Department of Urology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India

Address for Correspondence:
Dr. Nirmal Kumar Bhattacharyya,
Flat-4A, Shanti Apartment, 7/3, Motijheel Avenue, Kolkata - 700 074, West Bengal, India.
E-mail: drnbhattacharya@yahoo.co.in

ABSTRACT
Prostate gland is a fibromusculoglandular structure situated at the neck of urinary bladder. So, enlargement or growth of prostate due to nodular hyperplasia (NHP) or prostatic intraepithelial neoplasia (PIN) or adenocarcinoma may give rise to bladder outlet obstruction. Malignant growth i.e., PIN or adenocarcinoma cases are associated with increased blood level of prostate-specific antigen (PSA) and increased expression of different sex-steroid receptors because the growth is dependent on the interactions of androgen, progesterone and estrogen. The aim of our study is to correlate the histopathology, PSA levels and expression of different sex-steroid receptors by immunohistochemistry in different prostatic growth lesions. Among the total 50 cases received, inclusive of transurethral resection of prostate (TURP), transrectal ultrasound-guided biopsy and radical prostatectomy, 34 cases were diagnosed as NHP, 4 cases as PIN and 12 cases as adenocarcinoma histopathologically. Serum PSA values above 10 ng/ml were seen in 2 cases of PIN and 11 cases of adenocarcinoma and none of NHP. Estrogen receptor (ER) expressions were negative in all cases. Progesterone receptor (PR) expressions were strongly positive in 35% cases of both NHP and adenocarcinoma, whereas androgen receptor (AR) expressions were strong among all cases of adenocarcinoma and only in four cases of NHP. By observing these findings it can be suggested that antiandrogen and antiprogestrone therapy simultaneously will do better than antiandrogen alone in treating prostatic growth lesions.

Key words: Androgen receptor, immunohistochemistry, progesterone receptor, prostatic growth, prostate-specific antigen

INTRODUCTION
Prostate gland is a fibromusculoglandular structure situated at the neck of urinary bladder. So, enlargement or growth of prostate due to nodular hyperplasia (NHP) or prostatic intraepithelial neoplasia (PIN) or adenocarcinoma may give rise to bladder outlet obstruction. Malignant growth i.e., PIN or adenocarcinoma cases are associated with increased blood level of prostate-specific antigen (PSA) and increased expression of different sex-steroid receptors because the growth is dependent on the interactions of androgen, progesterone and estrogen. The aim of our study is to correlate the histopathology, PSA levels and expression of different sex-steroid receptors by immunohistochemistry in different prostatic growth lesions. Among the total 50 cases received, inclusive of transurethral resection of prostate (TURP), transrectal ultrasound-guided biopsy and radical prostatectomy, 34 cases were diagnosed as NHP, 4 cases as PIN and 12 cases as adenocarcinoma histopathologically. Serum PSA values above 10 ng/ml were seen in 2 cases of PIN and 11 cases of adenocarcinoma and none of NHP. Estrogen receptor (ER) expressions were negative in all cases. Progesterone receptor (PR) expressions were strongly positive in 35% cases of both NHP and adenocarcinoma, whereas androgen receptor (AR) expressions were strong among all cases of adenocarcinoma and only in four cases of NHP. By observing these findings it can be suggested that antiandrogen and antiprogestrone therapy simultaneously will do better than antiandrogen alone in treating prostatic growth lesions.

Key words: Androgen receptor, immunohistochemistry, progesterone receptor, prostatic growth, prostate-specific antigen

Prostatic enlargement or growth most commonly occurs due to nodular hyperplasia or due to neoplasia like adenocarcinoma of tubuloalveolar glands and also its precursor lesions – prostatic intraepithelial lesion (PIN). All these conditions arise in males after 50 years of age and are due to the effect of androgen released from testis. All these conditions cause bladder outlet obstruction giving rise to different clinical features like dysuria, retention of urine and enuresis. Low-back pain due to vertebral metastasis is common in the late stage of prostatic carcinoma. This malignancy, though uncommon in Asian countries, the incidence is increasing in our country 1% every year. The incidence of PIN is even higher, approximately 70% above the 70 years of age. To detect early this commonly occurring malignancy in men, screening tests are considered after the age of 40 years, which include digital rectal examination (DRE), transrectal ultrasonography (TRUS) and estimation of prostate-specific antigen (PSA) in serum. PSA is secreted by luminal epithelial cells of prostatic glands. Serum PSA level above 4 ng/ml is noted in most cases of adenocarcinoma of prostate and if it is increased more than 0.15 per unit volume of prostate (PSA density), it is indicative of adenocarcinoma of prostate.
Androgen receptor (AR) also known as NR3C4 is a type of nuclear receptor which is activated by binding of either of the androgenic hormones. The ARs are closely related to progesterone receptor (PR) and progestins in higher dose can block the ARs.

AR remains important in the development and progression of prostatic carcinoma and AR expression is maintained throughout prostate carcinoma progression and the majority of androgen-independent or hormone-refractory prostate carcinoma express AR. Estrogen receptor (ER) and estrogen are implicated in prostatic carcinogenesis and tumor progression. The PRs are also nuclear receptors and progressive emergence of PRs during tumor progression obviously reflects the ability of metastatic and androgen-insensitive tumors to use estrogens through an ER-α-mediated pathway. So, antiestrogens and SERMs can suppress progression of prostatic carcinoma.

Here, our objective of this study was to correlate the histopathology of prostatic tissues resected due to different growth with PSA level in serum and expression of AR, ER and PR by immunohistochemistry (IHC).

MATERIALS AND METHODS

The study was done in the Departments of Pathology and Urology of IPGMER, Kolkata, during the period of July 2008 to August 2010. A total of 50 cases were collected which were diagnosed in Urology Dpt. as cases of prostatic growth. Among them, 35 were Transurethral resection of prostate (TURP) specimens with clinicoradiological diagnosis of NHP, 05 were transurethral ultrasonography–guided biopsy (TRUS-BX) specimens and remaining 10 specimens were of radical prostatectomy specimens with clinicoradiologic and biochemical markers favoring prostatic adenocarcinoma.

Gross details of sent specimens along with clinical, radiological and serum PSA level of all patients were noted. Hematoxylin and Eosin (H&E)-stained sections were prepared for routine histopathological evaluation to see nature of growth including Gleason scoring in cases of carcinoma. Poly-l-Lysine-coated slides were used for immunohistochemical staining for AR, ER and PR. The different reagents for IHC were provided by Biogenex including positive control. AR, ER, and PR expressions were assessed by ‘Quick-Score’ as applied in breast tissue.

Statistical analysis was done by using STATISTICA data analysis software version 6.0 [Tulsa, Oklahoma; Statsoft, Inc., 2001] considering a ‘P’ value below 0.05 as significant.

RESULTS AND ANALYSIS

We studied total fifty (50) cases including TURP, TRUS-BX and specimens of radical prostatectomy of which 34 cases were diagnosed as NHP (68%), 4 cases as PIN (8%) and 12 cases as prostatic adenocarcinoma (24%) as per routine histopathology [Figure 1].

The mean age was 68.66 years. Among all only 7 patients were under 60 years, 22 were between 61 and 70 years, 17 were between 71 and 80 years and 4 patients were above 80 years of age. Among the 34 cases of NHP, 6 cases were under 60 years, whereas 3 cases were above 80 years. All cases of PIN were noted above 70 years of age. Among the carcinoma cases 7 cases were seen in between 71 and 80 years of age, 3 cases were between 61 and 70 years, and one case each below 60 years and above 80 years.

PSA values >10 ng/ml were noted in 11 cases of carcinoma and among which 7 cases had >100 ng/ml. Twenty-nine cases of NHP subjects had PSA values <4 ng/ml and rest 5 cases had PSA values within range between 4 and 10 ng/ml. In two cases of PIN, PSA were between 4 and 10 ng/ml and other two cases had PSA values within range between 11 and 99 ng/ml [Table 1]. Higher PSA values ranging between 55.6 and 1011.3 were observed in nine cases of prostatic adenocarcinoma with a high Gleason score between 8 and 10, whereas it was in the range of 12.13-57 in cases with score 7 (2 cases) and one case with score 6 had PSA value 8.2 [Table 2].

ER expressions analyzed by immunostaining were negative in all cases. PR expression was strongly positive in 10 cases of NHP, 1 case of PIN and 4 cases of Prostatic adenocarcinoma. The remaining cases were negative [Figure 2].

AR expression was strongly positive in 4 cases of NHP, 2 cases of PIN and all 12 cases of adenocarcinoma. It was
weakly positive in 30 cases of NHP and 2 cases of PIN. None was negative [Table 3 and Figure 3].

**DISCUSSION**

In this study, it was found that all the patients of prostatic growth were in the older age group.

The mean age was 68.66 years. No significant age difference was detected between benign and malignant cases. Men et al. found similar age distribution. They found the mean age to be 64.67 years for prostatic growth lesions.[8]

<table>
<thead>
<tr>
<th>Table 1: (PSA values in different prostatic growth)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histopathologic types</strong></td>
</tr>
<tr>
<td>NHP</td>
</tr>
<tr>
<td>PIN</td>
</tr>
<tr>
<td>Prostatic carcinoma</td>
</tr>
</tbody>
</table>

NHP is the most common finding in routine histopathological examination followed by prostatic adenocarcinoma and PIN, respectively, the results corroborating the results of Men et al.

A majority of NHP cases had normal serum PSA values. Only three cases had the values falling in the grey zone. Two cases had significantly raised PSA values, whereas 50% of PIN cases had PSA values falling in the grey zone. Among the 11 cases of carcinoma with raised PSA, 7 cases had it >100 ng/ml. Mean PSA was significantly higher in carcinoma than that of NHP and PIN. Serum PSA values were much higher in carcinoma than that of NHP with *P* value 0.00001, which is also corroborated by the results of study by Aboseif et al.[9]

In our study, 75% of the adenocarcinoma cases showed higher Gleason scoring between 8 and 10. This finding is identical to the study results of Humphrey.[10]

So, in our study, higher serum PSA was seen in cases with higher Gleason score showing a positive correlation.

ER expression in prostate tissues was negative in all cases of NHP, PIN and prostate carcinoma. These IHC results were identical to that of other studies such as Wernert[11] and Kang et al.[12] Wernert et al. found the ER and PR were demonstrated by IHC in nuclei of periglandular fibrocytes and smooth muscle cells and hyperplastic basal cells, but glandular secretory epithelium were negative and thus in prostatic carcinoma cases

Table 2: PSA values in different Gleason scores of prostatic carcinoma

<table>
<thead>
<tr>
<th>Gleason score</th>
<th>PSA values</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-4</td>
<td>Not applicable</td>
</tr>
<tr>
<td>5-6</td>
<td>8.2</td>
</tr>
<tr>
<td>7</td>
<td>12.13-57</td>
</tr>
<tr>
<td>8-10</td>
<td>55.6-1011.3</td>
</tr>
</tbody>
</table>

ER expression in prostate tissues was negative in all cases of NHP, PIN and prostate carcinoma. These IHC results were identical to that of other studies such as Wernert[11] and Kang et al.[12] Wernert et al. found the ER and PR were demonstrated by IHC in nuclei of periglandular fibrocytes and smooth muscle cells and hyperplastic basal cells, but glandular secretory epithelium were negative and thus in prostatic carcinoma cases

Table 3: PR and AR expression in different prostatic growths

<table>
<thead>
<tr>
<th>Histologic diagnosis</th>
<th>PR expression</th>
<th>AR expression</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>negative</td>
<td>Weakly +ve</td>
</tr>
<tr>
<td>NHP</td>
<td>06</td>
<td>18</td>
</tr>
<tr>
<td>PIN</td>
<td>03</td>
<td>0</td>
</tr>
<tr>
<td>Prostatic carcinoma</td>
<td>07</td>
<td>01</td>
</tr>
</tbody>
</table>

Figure 2: (a) Nodular hyperplasia of prostate (monoclonal antibody against progesterone receptors ×1000). (b) Prostatic adenocarcinoma (monoclonal antibody against progesterone receptors ×400)

Figure 3: (a) Nodular hyperplasia of prostate (monoclonal antibody against androgen receptors ×400). (b) Prostatic adenocarcinoma (monoclonal antibody against androgen receptors ×400)
in their study ER and PR were negative. They concluded that estrogens might contribute to NHP by triggering stromal proliferation with a secondary inductive epithelial growth. Obviously, they do not act directly on prostatic carcinoma but inhibit growth via the hypophyseal-testicular axis. The biologic significance of the PR in prostatic carcinoma is unknown. The PR expressions of carcinoma cells and stromal cells in prostatic carcinoma were found in 93.3% and 76.7%, respectively. The PR were immunoreactive in stromal cells around carcinoma cells, as demonstrated in studies done by Kang et al.,[13] Hiramatsu[13] and Bonkhoff et al.[14]

In our study, 82.35% of NHP cases showed PR expression (including weak expression also), whereas 41.67% of carcinoma cases showed PR expression. In Fisher’s exact test (two-tailed), a P value was 0.021 between NHP and carcinoma cases, which is statistically significant.

All the prostatic growth lesions in our study were positive for AR expression with varying staining intensity. Only 11.78% of NHP cases, 50% of PIN cases and 100% of carcinoma cases showed strongly positive AR expression. So, prostatic carcinoma cases showed highest content of AR among other prostatic lesions. It is statistically significant (P value < 0.0001) between carcinoma and NHP. Our study showed identical result of AR expression in prostatic lesions to the studies done by Qui Yi-Q et al.[13] and Brolin et al.[14] Qui-Yi-Q et al. had done a study to evaluate AR expression in clinically localized prostatic carcinoma. AR immunoreactivity is almost exclusively nuclear and was observed in tumor cells, non-neoplastic glandular epithelial cells and a proportion of peritumoral stromal cells. Mean percentages of AR-positive cells were significantly higher in cancer tissues compared to that in normal prostatic tissues (P < 0.0001). A comparison with Gleason score yielded similar correlation. Brolin et al. analyzed AR, PR and ER contents in cytosol and salt-extractable nuclear subcompartments from 6 normal, 39 NHP and 7 malignant prostatic tissue specimens using the radioligand-binding assay technique. The highest content was found in the cytosol and nucleic acid from malignant prostatic tissues.

CONCLUSION

From this study, we observed that among our patients with a mean age of 68.66 years whose specimens of prostate were sent from urology department to our pathology department for the histopathological study, NHP cases were most common and PIN were least common. Serum PSA was within normal limits in NHP cases, but higher in prostatic carcinoma cases and also more in higher Gleason score and grey-zone in PIN cases. Sex-steroid receptor status as seen by IHC was divergent in different types of prostatic growth lesions. PR was positive in most cases of NHP and almost half of carcinoma cases. All lesions showed positive staining of AR with highest expression in carcinoma cases. But, all cases were ER negative. With these findings, antiandrogen and antiprogesterone therapy may be indicated in the treatment of prostatic adenocarcinoma.

REFERENCES

5. Androgen receptor, Wikipedia, the free encyclopedia, 22 September, 2010.